Drugs / vormatrogine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07287163 | Oct 2025 → May 2028 expected | epilepsy with generalized tonic-clonic seizures, focal epilepsy | Praxis Precision Medicines | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vormatrogine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07287163 ↗ |
| Route | Oral | “Once daily oral” NCT07287163 ↗ |